Most Important Outcomes Research Papers on Stroke and Transient Ischemic Attack
暂无分享,去创建一个
Isuru Ranasinghe | Ruijun Chen | S. Nuti | I. Ranasinghe | R. Dreyer | Serene I. Chen | K. Murugiah | K. Dharmarajan | Kumar Dharmarajan | Karthik Murugiah | B. Wayda | Ruijun Chen | Rachel Dreyer | Sudhakar V Nuti | Serene I Chen | Brian Wayda | Brian Wayda
[1] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[2] Douglas G Altman,et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses , 2003, BMJ : British Medical Journal.
[3] D. Berlowitz,et al. Hypertension control: how well are we doing? , 2003, Archives of internal medicine.
[4] M. Kaste,et al. Effectiveness of Primary and Comprehensive Stroke Centers: PERFECT Stroke: A Nationwide Observational Study From Finland , 2010, Stroke.
[5] Adrian F Hernandez,et al. Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke: Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes , 2011, Circulation.
[6] Eric E. Smith,et al. Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke , 2010, Circulation. Cardiovascular quality and outcomes.
[7] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[8] H. Uno,et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] Eric E. Smith,et al. Are Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation? , 2011, Circulation. Cardiovascular quality and outcomes.
[10] Maurice Buchbinder,et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.
[11] W. Baker,et al. Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States , 2009, Journal of managed care pharmacy : JMCP.
[12] A. Tonkin,et al. Statins for stroke prevention: disappointment and hope. , 2004, Circulation.
[13] V. Pavlik,et al. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. , 2000, Archives of internal medicine.
[14] Keun-Hwa Jung,et al. Secular Trends in Ischemic Stroke Characteristics in a Rapidly Developed Country: Results From the Korean Stroke Registry Study (Secular Trends in Korean Stroke) , 2012, Circulation. Cardiovascular quality and outcomes.
[15] R E Latchaw,et al. Recommendations for the establishment of primary stroke centers , 2000 .
[16] R. Nelson,et al. The cost-effectiveness of telestroke in the treatment of acute ischemic stroke , 2011, Neurology.
[17] Jeffrey L Saver,et al. The Impact of Recanalization on Ischemic Stroke Outcome: A Meta-Analysis , 2007, Stroke.
[18] J. Broderick,et al. Impact of Onset-to-Reperfusion Time on Stroke Mortality: A Collaborative Pooled Analysis , 2013, Circulation.
[19] Gustavo Saposnik,et al. IScore: A Risk Score to Predict Death Early After Hospitalization for an Acute Ischemic Stroke , 2011, Circulation.
[20] J. Tu,et al. Rhythm Versus Rate Control Therapy and Subsequent Stroke or Transient Ischemic Attack in Patients With Atrial Fibrillation , 2012, Circulation.
[21] R. Sacco,et al. Further good news on stroke, but no time for rest. , 2011, Circulation.
[22] S Claiborne Johnston,et al. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling , 2009, The Lancet Neurology.
[23] R. Sacco,et al. Translating Evidence Into Practice: A Decade of Efforts by the American Heart Association/American Stroke Association to Reduce Death and Disability Due to Stroke: A Presidential Advisory From the American Heart Association/American Stroke Association , 2010, Stroke.
[24] Sudha Seshadri,et al. Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. , 2006, JAMA.
[25] D. Bravata,et al. Prevalence of Inadequate Blood Pressure Control Among Veterans After Acute Ischemic Stroke Hospitalization: A Retrospective Cohort , 2011, Circulation. Cardiovascular quality and outcomes.
[26] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[27] P. Neužil,et al. Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial , 2013, Circulation.
[28] Li Liang,et al. Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2009, Circulation.
[29] J. Saver,et al. Declining Stroke and Vascular Event Recurrence Rates in Secondary Prevention Trials Over the Past 50 Years and Consequences for Current Trial Design , 2011, Circulation.
[30] Richard Horton,et al. GBD 2010: understanding disease, injury, and risk , 2012, The Lancet.
[31] J. Avorn. The relative cost-effectiveness of anticoagulants: obvious, except for the cost and the effectiveness. , 2011, Circulation.
[32] D. Bravata,et al. Use of Antithrombotic Medications Among Elderly Ischemic Stroke Patients , 2011, Circulation. Cardiovascular quality and outcomes.
[33] H. Uno,et al. Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa: The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience , 2011, Circulation.
[34] Jun Zhu,et al. Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[35] Eric E. Smith,et al. Use of Tissue-Type Plasminogen Activator Before and After Publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke , 2012, Circulation. Cardiovascular quality and outcomes.
[36] Jeffrey L Saver,et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. , 2009, Stroke.
[37] Jeroen J. Bax,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[38] J. Kluger,et al. Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin , 2012, Circulation. Cardiovascular quality and outcomes.
[39] Scott Hamilton,et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.
[40] Pamela W Duncan,et al. Management of Adult Stroke Rehabilitation Care: a clinical practice guideline. , 2005, Stroke.
[41] Sharon-Lise T. Normand,et al. An Administrative Claims Measure Suitable for Profiling Hospital Performance on the Basis of 30-Day All-Cause Readmission Rates Among Patients With Heart Failure , 2008, Circulation. Cardiovascular quality and outcomes.
[42] Eric E. Smith,et al. Risk Score for In-Hospital Ischemic Stroke Mortality Derived and Validated Within the Get With The Guidelines–Stroke Program , 2010, Circulation.
[43] Harlan M. Krumholz,et al. An Administrative Claims Measure Suitable for Profiling Hospital Performance Based on 30-Day All-Cause Readmission Rates Among Patients With Acute Myocardial Infarction , 2011, Circulation. Cardiovascular quality and outcomes.
[44] Geoff Cohen,et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.
[45] D. Singer,et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.
[46] A. Camm,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.
[47] Eric E. Smith,et al. Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines–Stroke Hospitals , 2013 .
[48] S. Solomon,et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.
[49] T. Meinertz,et al. Event‐Recorder Monitoring in the Diagnosis of Atrial Fibrillation in Symptomatic Patients: Subanalysis of the SOPAT Trial , 2006, Journal of cardiovascular electrophysiology.
[50] G. Lip,et al. Added Predictive Ability of the CHA2DS2VASc Risk Score for Stroke and Death in Patients With Atrial Fibrillation: The Prospective Danish Diet, Cancer, and Health Cohort Study , 2012, Circulation. Cardiovascular quality and outcomes.
[51] A. Verma,et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. , 2011, The Canadian journal of cardiology.
[52] Sebastian Schneeweiss,et al. Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation , 2012, Circulation. Cardiovascular quality and outcomes.
[53] Harlan M Krumholz,et al. An Administrative Claims Model Suitable for Profiling Hospital Performance Based on 30-Day Mortality Rates Among Patients With Heart Failure , 2006, Circulation.
[54] Salim Yusuf,et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[55] H. Crijns,et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .
[56] A. Torbicki,et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. , 2004, Chest.
[57] Amanda H. Salanitro,et al. Estimating and Reporting on the Quality of Inpatient Stroke Care by Veterans Health Administration Medical Centers , 2012, Circulation. Cardiovascular quality and outcomes.
[58] D. Xavier,et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .
[59] D. Singer,et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.
[60] Mark D. Huffman,et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.
[61] D. Packer,et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. , 2006, American heart journal.
[62] S. Yusuf,et al. Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy , 2012, Circulation.
[63] Leandro Provinciali,et al. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .
[64] Michal Abrahamowicz,et al. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. , 2005, American journal of epidemiology.
[65] M. Kaste,et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.
[66] Eric E. Smith,et al. Emergency Medical Service Hospital Prenotification Is Associated With Improved Evaluation and Treatment of Acute Ischemic Stroke , 2012, Circulation. Cardiovascular quality and outcomes.
[67] R. Nogueira,et al. “Picture to Puncture”: A Novel Time Metric to Enhance Outcomes in Patients Transferred for Endovascular Reperfusion in Acute Ischemic Stroke , 2013, Circulation.
[68] D. Singer,et al. Risks and Benefits of Anticoagulation in Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry , 2013, Circulation. Cardiovascular quality and outcomes.
[69] Hardeep Singh,et al. Quality of Care for Hypertension and Diabetes in Federal- Versus Commercial-Managed Care Organizations , 2004, American journal of medical quality : the official journal of the American College of Medical Quality.
[70] L. Prokop,et al. Endovascular therapy for acute ischemic stroke: a systematic review and meta-analysis. , 2013, Mayo Clinic proceedings.
[71] J. McNeil,et al. Greater Incidence of Both Fatal and Nonfatal Strokes in Disadvantaged Areas: The Northeast Melbourne Stroke Incidence Study , 2006, Stroke.
[72] D. Bravata,et al. Does the Inclusion of Stroke Severity in a 30-Day Mortality Model Change Standardized Mortality Rates at Veterans Affairs Hospitals? , 2012, Circulation. Cardiovascular quality and outcomes.
[73] A. Tjønneland,et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: A population-based prospective cohort study of 57,053 men and women in Denmark , 2007, Scandinavian journal of public health.
[74] P. Heuschmann,et al. Effects of the implementation of a telemedical stroke network: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria, Germany , 2006, The Lancet Neurology.
[75] Mårten Rosenqvist,et al. Stepwise Screening of Atrial Fibrillation in a 75-Year-Old Population: Implications for Stroke Prevention , 2013, Circulation.
[76] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[77] Eric E. Smith,et al. Improving Door-to-Needle Times in Acute Ischemic Stroke: The Design and Rationale for the American Heart Association/American Stroke Association's Target Stroke Initiative , 2011, Stroke.
[78] V. Feigin,et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review , 2009, The Lancet Neurology.
[79] N. Ammash,et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographics tudy , 1995 .
[80] G. Diamond,et al. Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 1: diagnosis of stable ischemia and ischemic heart disease. , 2004, Circulation.
[81] G. Saposnik,et al. The iScore Predicts Functional Outcome in Korean Patients With Ischemic Stroke , 2013, Stroke.
[82] M. Wintermark,et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.
[83] Alan D. Lopez,et al. Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.
[84] R. de Caterina,et al. Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation , 2013, Circulation.
[85] R. Tamblyn,et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. , 1995, Journal of clinical epidemiology.
[86] Harlan M Krumholz,et al. Development, validation, and results of a measure of 30-day readmission following hospitalization for pneumonia. , 2011, Journal of hospital medicine.
[87] Anthony S. Kim,et al. Global Variation in the Relative Burden of Stroke and Ischemic Heart Disease , 2011, Circulation.
[88] B. Popkin,et al. The nutrition transition and obesity in the developing world. , 2001, The Journal of nutrition.
[89] Jiaquan Xu,et al. Deaths: final data for 2008. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[90] J. Leonardi-Bee,et al. Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events: A Systematic Review , 2003, Stroke.
[91] Thomas Lumley,et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. , 2003, JAMA.
[92] J. Switzer,et al. Cost-Effectiveness of Hub-and-Spoke Telestroke Networks for the Management of Acute Ischemic Stroke From the Hospitals’ Perspectives , 2013, Circulation. Cardiovascular quality and outcomes.
[93] Ning Zhang,et al. External Validation of the iScore for Predicting Ischemic Stroke Mortality in Patients in China , 2013, Stroke.
[94] Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000 , 2003 .
[95] Stephen Prudhomme,et al. Revised and Updated Recommendations for the Establishment of Primary Stroke Centers: A Summary Statement From the Brain Attack Coalition , 2011, Stroke.
[96] G. Schuler,et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. , 2007, Journal of the American College of Cardiology.
[97] B. Gage,et al. Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation , 2010, Circulation.
[98] E. Peterson,et al. Patterns of Emergency Medical Services Use and Its Association With Timely Stroke Treatment: Findings From Get With the Guidelines-Stroke , 2013, Circulation. Cardiovascular quality and outcomes.
[99] S. Solomon,et al. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. , 2005, American heart journal.
[100] A. Khera,et al. Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.
[101] S. Normand,et al. An Administrative Claims Model Suitable for Profiling Hospital Performance Based on 30-Day Mortality Rates Among Patients With an Acute Myocardial Infarction , 2006, Circulation.